ONCAlert | Upfront Therapy for mRCC
Videos  >  

Findings for the Combination of Anti-TIM-3 and Anti-PD-1 in Melanoma and Lung Cancer

Diwakar Davar, MBBS, MSc
Published Online:6:39 PM, Thu December 27, 2018


Diwakar Davar, MBBS, MSc, assistant professor of medicine and medical oncologist/hematologist at UPMC Hillman Cancer Center, discusses how data from a phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.

PD-1 checkpoint inhibition has been dominant in the treatment paradigm, says Davar, as it produces significant responses in both disease settings. According to these data, this combination is both safe and efficacious in patients who are refractory to PD-1.

Interestingly, these findings included patients with lung cancer and melanoma who were heavily pretreated, as well. Investigators also found a relationship between dosing and efficacy; increasing the dose of the agents relates to increased efficacy.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.